PRIOR AUTHORIZATION CRITERIA

BRAND NAME (generic)

JUBLIA (efinaconazole topical solution)

Status: CVS Caremark Criteria

Type: Initial Prior Authorization with Quantity Limit

POLICY

FDA-APPROVED INDICATIONS

Jublia (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to *Trichophyton rubrum* and *Trichophyton mentagrophytes*.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

• The requested drug is being prescribed for onychomycosis of the toenail(s) due to *Trichophyton rubrum* or *Trichophyton mentagrophytes*

AND

• The patient's diagnosis has been confirmed with a fungal diagnostic test (e.g., potassium hydroxide [KOH] preparation, fungal culture, or nail biopsy)

AND

The patient has experienced an inadequate treatment response to an oral antifungal therapy (e.g., terbinafine, itraconazole)

OR

- The patient has experienced an intolerance to an oral antifungal therapy (e.g., terbinafine, itraconazole)
 OR
- The patient has a contraindication that would prohibit a trial of an oral antifungal therapy (e.g., terbinafine, itraconazole)

AND

The requested drug is not being used in a footbath

AND

If additional quantities are required, multiple toenails are being treated

Quantity Limits apply.

Treatment of a single nail: 4 mL per 21 days* or 12 mL per 63 days*

Treatment of multiple nails: 16 mL per 21 days* or 48 mL per 63 days*

*The duration of 21 days is used for a 28-day fill period and 63 days is used for an 84-day fill period to allow time for refill processing.

REFERENCES

- 1. Jublia [package insert]. Bridgewater, NJ: Bausch Health US LLC; March 2022.
- Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2022; Accessed July 17, 2022.
- 3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www.micromedexsolutions.com. Accessed July 17, 2022.
- 4. Kreijkamp-Kaspers S, Hawke K, Guo L, et al. Oral antifungal medication for toenail onychomycosis. *Cochrane Database Syst Rev.* 2017;7:CD010031.
- 5. Centers for Disease Control (CDC) and Prevention. Fungal Nail infections. https://www.cdc.gov/fungal/nail-infections.html. Accessed July 29, 2022.

Jublia PA with Limit Policy 1160-C 10-2022

©2022 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

6.	Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two
	phase III multicenter randomized, double-blind studies. J Am Acad Dermatol. 2013;68:600-608.
7.	Lipner SR, Scher RK. Efinaconazole in the treatment of onychomycosis. <i>Infect Drug Resist</i> . 2015;8:163–172.